OSELTAMIVIR PHOSPHATE

Post-LOE

Alvogen

ANDAORALFOR SUSPENSION

Approved

Oct 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

OSELTAMIVIR PHOSPHATE by Alvogen is 12. Approved for acute, uncomplicated illness due to influenza a, b infection in patients 2 weeks of age and 3 more indications. First approved in 2017.

Drug data last refreshed 5h ago

$0.0BPart D

Mechanism of Action

12.1 Mechanism of Action Oseltamivir is an antiviral drug with activity against influenza virus [see ]. 12.3 Pharmacokinetics Absorption and Bioavailability Oseltamivir is absorbed from the gastrointestinal tract after oral administration of oseltamivir phosphate and is extensively converted…

Worked on OSELTAMIVIR PHOSPHATE at Alvogen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

OSELTAMIVIR PHOSPHATE

Mechanism of Action

Indications (6)

Clinical Trials (1)